



*Roche Finance Europe B.V. -
Financial Statements 2012*

Management Report

1. Review of the year ended 31 December 2012

General

Roche Finance Europe B.V., a company registered in the Netherlands (hereafter 'the Company'), is 100% indirectly owned by Roche Holding Ltd, a public company registered in Switzerland and parent company of the Roche Group. The main activity of the Company is the provision of financing to other affiliates of the Roche Group. Refinancing takes place on the bond or loan markets.

Important events

On 23 March 2012 the Company issued EUR denominated fixed rate 2.0% notes due 25 June 2018 with a principal amount of 1,000 million EUR. The net proceeds were 996 million EUR and the effective interest rate is 2.07%. These notes are guaranteed by Roche Holding Ltd, the parent company of the Roche Group. On the same date the Company granted loans to related parties in the aggregate amount of 1,000 million EUR and all due 25 June 2018. The effective interest rate is 3.50%.

Financial position and performance

Besides the issuance of notes and loans as described in the important events section above, the financial performance and the financial position of the Company did not change materially.

Employees

The Company has no employees. Roche Pharmholding B.V., Woerden, performs all administrative activities on behalf of the Company.

Results

Net income of the financial year is 266 thousand EUR (2011: 60 thousand EUR).

Future outlook

The Company will continue its current activities in 2013. No changes in the activities of the Company are expected.

2. Principal risks and uncertainties

Risks

The Company is exposed to various financial risks arising from its financing activities.

Credit Risk

The Company is exposed to potential default of payment of any of its loans receivable from other affiliates of the Roche Group. Therefore the credit risk ultimately depends on the financial position of the Roche Group.

Market and Liquidity Risk

The exposure to interest rates and foreign exchange rates is limited, because interest rates, duration and terms of financial assets and liabilities as well as their currency are generally matching. Therefore, the liquidity risk is reduced as well. Moreover, the Company's obligations to third parties on the bond markets are guaranteed by Roche Holding Ltd, the parent company of the Roche Group and covered by loan receivables from other members of the Roche Group that have the same maturity. In addition, the Company has access (jointly with other borrowers of the Group) to a currently unused committed credit line with various financial institutions of 3.9 billion EUR.

The Company's financial risk management is described in the Notes to the Financial Statements in more detail.

Uncertainties

The main activity of the Company is to provide financing to other members of the Roche Group and to refinance this on the bond or loan markets. Depending on decisions of management, the Company may potentially issue new debt securities and/or borrow funds to finance other members of the Roche Group.

Various known and unknown risks, uncertainties and other factors could lead to substantial differences between the actual and future results, financial situation development or performance of the Company and the historical results given in the Management Report and the Financial Statements.

3. Responsibility statement

The directors of Roche Finance Europe B.V. confirm that, to the best of their knowledge as of the date of their approval of the audited financial statements as at 31 December 2012:

- the audited financial statements as at 31 December 2012, which have been prepared in accordance with the applicable set of accounting standards, give a true and fair view of the assets, liabilities, financial position and profit or loss of Roche Finance Europe B.V. taken as a whole; and
- the management report gives a true and fair view of the development and performance of the business and the position of Roche Finance Europe B.V. together with a description of the principal risks and uncertainties that it faces.

Woerden, 28 January, 2013

The Board of Directors

B.L.A. Vanhauwere

J.W. van den Broek

P. Eisenring

D.F. Heinis

Roche Finance Europe B.V. Financial Statements

Reference numbers indicate the corresponding Notes to the Financial Statements.

Roche Finance Europe B.V., statement of comprehensive income *in millions of EUR*

	Year ended 31 December	
	2012	2011
Income		
Financial income – related parties ²	41	29
Total income	41	29
Expenses		
Financing costs ²	(30)	(29)
Guarantee fees – related parties ²	(11)	-
Other	-	-
Total expenses	(41)	(29)
Profit before taxes	-	-
Income tax	-	-
Net income	-	-
Other comprehensive income	-	-
Total comprehensive income	-	-

Roche Finance Europe B.V., balance sheet *in millions of EUR*

	31 December 2012	31 December 2011	31 December 2010
Non-current assets			
Long-term loans receivable – related parties ⁶	1,240	233	285
Total non-current assets	1,240	233	285
Current assets			
Short-term loans receivable – related parties ⁶	-	-	-
Accounts receivable – related parties ⁷	25	17	18
Cash and cash equivalents ⁸	-	-	-
Total current assets	25	17	18
Total assets	1,265	250	303
Non-current liabilities			
Long-term debt ¹⁰	(1,238)	(235)	(287)
Deferred income tax liabilities ⁴	-	-	-
Total non-current liabilities	(1,238)	(235)	(287)
Current liabilities			
Short-term debt ¹⁰	-	-	-
Current income tax liabilities ⁴	-	-	-
Accounts payable – related parties	-	-	-
Accrued interest on debt instruments ⁹	(16)	(4)	(5)
Total current liabilities	(16)	(4)	(5)
Total liabilities	(1,254)	(239)	(292)
Total net assets	11	11	11
Equity			
Share capital ¹¹	2	2	2
Retained earnings	9	9	9
Unappropriated result	-	-	-
Total equity	11	11	11

Roche Finance Europe B.V., statement of cash flows *in millions of EUR*

	Year ended 31 December	
	2012	2011
Cash flows from operating activities		
Net income	-	-
Add back non-operating (income) expense	-	-
- Financial income – related parties ²	(41)	(29)
- Financing costs ²	30	29
- Guarantee fees – related parties ²	11	-
- Income taxes	-	-
- Income taxes paid	-	-
Total cash flow from operating activities	-	-
Cash flows from investing activities		
Issue of long-term loans receivable – related parties ⁶	(1,000)	-
Proceeds from repayment of loans receivable – related parties ⁶	-	71
Interest received – related parties	23	16
Total cash flow from investing activities	(977)	87
Cash flows from financing activities		
Proceeds from issue of bonds and notes ¹⁰	996	-
Repayment and redemption of bonds and notes ¹⁰	-	(71)
(Increase) decrease of cash pool balance with related parties	10	-
Guarantee fees paid – related parties	(11)	-
Interest paid	(18)	(16)
Total cash flow from financing activities	977	(87)
Net effect of currency translation on cash and cash equivalents	-	-
Increase (decrease) in cash and cash equivalents	-	-
Cash and cash equivalents at 1 January	-	-
Cash and cash equivalents at 31 December ⁸	-	-

Roche Finance Europe B.V., statement of changes in equity *in millions of EUR*

	Share capital	Retained earnings	Unappropriated result	Total
Year ended 31 December 2011				
At 1 January 2011	2	9	-	11
Net income	-	-	-	-
Other comprehensive income	-	-	-	-
Total comprehensive income	-	-	-	-
Appropriation of result	-	-	-	-
At 31 December 2011	2	9	-	11
Years ended 31 December 2012				
At 1 January 2012	2	9	-	11
Net income	-	-	-	-
Other comprehensive income	-	-	-	-
Total comprehensive income	-	-	-	-
Appropriation of result	-	-	-	-
At 31 December 2012	2	9	-	11

Notes to the Roche Finance Europe B.V. Financial Statements

Reference numbers indicate corresponding Notes to the Financial Statements.

1. Summary of significant accounting policies

Basis of preparation of the Financial Statements

These financial statements are the Financial Statements of Roche Finance Europe B.V., a company incorporated in the Netherlands ('the Company'). The Company is 100% indirectly owned by Roche Holding Ltd, a public company registered in Switzerland and parent company of the Roche Group, and therefore the Company is part of the Roche Group. The main activity of the Company is the provision of financing to other affiliates of the Roche Group. Refinancing takes place on the bond or loan markets.

Statement of compliance

The Financial Statements have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union and with Part 9 of Book 2 of the Netherlands Civil Code. They have been prepared using the historical cost convention. They were approved for issue by the Board of Directors on 28 January 2013.

Use of estimates and judgements

The preparation of the Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities at the date of the Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgement at the date of the Financial Statements, deviate from the actual circumstances, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

Segment reporting

The Company has only one operating segment and undertakes its operations in the Netherlands. Therefore no segment reporting is included in these Financial Statements.

Foreign currency translation

The functional currency of the Company is Euro (EUR). Transactions in other currencies are initially reported using the exchange rate at the date of the transaction. Assets and liabilities in currencies other than EUR have been translated into EUR at year-end-market rate. Gains and losses from the settlement of such transactions and gains and losses on translation of monetary assets and liabilities denominated in other currencies than EUR are included in income.

Fair values

Fair value is the amount for which a financial asset, liability or instrument could be exchanged between knowledgeable and willing parties in an arm's length transaction. It is determined by reference to quoted market prices or by the use of established valuation techniques such as option pricing models and the discounted cash flow method if quoted prices in an active market are not available ('Fair value hierarchy'). Valuation techniques will incorporate observable market data about market conditions and other factors that are likely to affect the fair value of a financial instrument. Valuation techniques are typically used for derivative financial instruments. The fair values of financial assets and liabilities at the reporting date are not materially different from their reported carrying values unless specifically mentioned in the Notes to the Financial Statements.

Accounts receivable

Accounts receivable are carried at the original invoice amount less allowances made for doubtful accounts. An allowance for doubtful accounts is recorded for the difference between the carrying value and the recoverable amount where there is objective evidence that the Company will not be able to collect all amounts due.

Cash and cash equivalents

Cash and cash equivalents include cash on hand and time, call and current balances with banks and similar institutions. Such balances are only reported as cash if they are readily convertible to known amounts of cash, are subject to insignificant risk of changes in value and have a maturity of three months or less from the date of acquisition. This definition is also used for the statement of cash flows.

Loans and receivables

Loans and receivables are financial assets created by the Company or acquired from the issuer in a primary market. They are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Loans and receivables are initially recorded at fair value, including transaction costs, and are subsequently carried at amortised cost using the effective interest rate method.

Loans and receivables are assessed individually for possible impairment at each reporting date. An impairment charge is recorded where there is objective evidence of impairment, such as where the issuer is in bankruptcy, default or other significant financial difficulty. An impairment charge is the difference between the carrying value and the recoverable amount, calculated using estimated future cash flows discounted using the original effective interest rate.

A financial asset is derecognised when the contractual cash flows from the asset expire or when the Company transfers the rights to receive the contractual cash flows from the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. Any interest in transferred financial assets that is created or retained by the Company is recognised as a separate asset or liability.

Debt instruments

Debt instruments are initially recorded at cost, which is the proceeds received, net of transaction costs. Subsequently they are reported at amortised cost. Any discount between the net proceeds received and the principal value due on redemption is amortised over the duration of the debt instrument and is recognised as part of financing costs using the effective interest rate method. The Company derecognises a financial liability when its contractual obligations are discharged, cancelled or expired.

Finance income and finance costs

Finance income comprises interest income on funds invested. Interest income is recognized as it accrues in profit or loss, using the effective interest method.

Finance costs comprise interest expense on borrowings and impairment losses recognized on financial assets.

Taxation

Income taxes include all taxes based upon the taxable profits of the Company using the tax rates that are enacted or substantially enacted at the balance sheet date, including withholding taxes payable on the distribution of retained earnings within the Roche Group. Other taxes not based on income, such as property and capital taxes, are included within other expenses.

Deferred income tax assets and liabilities are recognised on temporary differences between the tax bases of assets and liabilities and their carrying values in the financial statements. Deferred income tax assets relating to the carry-forward of unused tax losses are recognised to the extent that it is probable that future taxable profit will be available against which the unused tax losses can be utilised.

Current and deferred income tax assets and liabilities are offset when the income taxes are levied by the same taxation authority and when there is a legally enforceable right to offset them. Deferred income taxes are determined based on the currently enacted or substantially enacted tax rates applicable in each tax jurisdiction where the Company operates.

Management judgements made in applying accounting policies

The application of the Company's accounting policies may require management to make judgements, apart from those involving estimates, that can have a significant effect on the amounts recognised in the financial statements. Management judgement may be particularly required when assessing the substance of transactions that have a complicated structure or legal form. There were no transactions that required specific application of management judgement in these financial statements.

Key assumptions and sources of estimation uncertainty

The preparation of the financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income, expenses and related disclosures. The estimates and underlying assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making the judgements about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an on-going basis. Changes in accounting estimates may be necessary if there are changes in the circumstances on which the estimate was based, or as a result of new information or more experience. Such changes are recognised in the period in which the estimate is revised.

There are currently no key assumptions about the future and no key sources of estimation uncertainty that the Company's management believe have a significant risk of causing a material adjustment to the carrying value of assets and liabilities within the next twelve months.

Changes in accounting policies adopted by the Roche Group and, consequently, by the Company

Changes in accounting policies that arise from the application of new or revised standards and interpretations are applied retrospectively, unless otherwise specified in the transitional requirements of the particular standard or interpretation. Retrospective application requires that the results of the comparative period and the opening balances of that period are restated as if the new accounting policy had always been applied. In some cases the transitional requirements of the particular standard or interpretation specify that the changes are to be applied prospectively. Prospective application requires that the new accounting policy only be applied to the results of the current period and the comparative period is not restated.

The Roche Group is currently assessing the potential impacts of new and revised standards and interpretations that will be effective from 1 January 2013 and beyond, and which the Group has not early adopted. The Company does not anticipate that these will have a material impact on the Company's overall results and financial position.

2. Financial income and financing costs

Financial income – related parties *in millions of EUR*

	Year ended 31 December	
	2012	2011
Interest income – related parties	41	15
Income from early repayment of loans – related parties ¹³	-	14
Total financial income – related parties	41	29

Financing costs *in millions of EUR*

	Year ended 31 December	
	2012	2011
Interest expense on debt instruments	(30)	(15)
Losses on redemption and repurchase of bonds and notes ¹⁰	-	(13)
Amortisation of debt discount ¹⁰	-	(1)
Guarantee fees – related parties	(11)	-
Total financing costs	(41)	(29)

3. Auditors remuneration

For the financial year KPMG Accountants N.V. charged net 18 thousand EUR to the Company for the audit of statutory financial statements and review of the interim financial statements.

4. Income taxes

Income tax expenses *in millions of EUR*

	Year ended 31 December	
	2012	2011
Current income taxes	-	-
Adjustment recognised for current tax of prior periods	-	-
Deferred income taxes	-	-
Total income (expense)	-	-

The Company's local statutory tax rate is 25.0% (2011: 25.0%) and this is also the effective tax rate in these financial statements.

Income tax assets (liabilities) *in millions of EUR*

	2012	2011	2010
Current income taxes			
- Assets	-	-	-
- Liabilities	-	-	-
Net current income tax assets (liabilities)	-	-	-
Deferred income taxes			
- Assets	-	-	-
- Liabilities	-	-	-
Net deferred income tax assets (liabilities)	-	-	-

5. Employee benefits

The Company has no employees. Roche Pharmholding B.V., Woerden, performs all administrative activities on behalf of the Company.

6. Loans receivable – related parties

GBP denominated loans

Loans receivable – related parties *in millions of EUR*

	2012	2011	2010
Roche Deutschland Holding GmbH, Germany, due 29 August 2023, outstanding principal 125 million GBP (2011: 125 million GBP; 2010: 125 million GBP), interest rate 5.67%	153	149	145
Roche Products Limited, United Kingdom, due 29 August 2023, transferred on 30 October 2012 to Roche Diagnostics Limited (outstanding principle 2011: 36 million GBP; 2010: 85 million GBP), interest rate 5.67%	-	42	99
Roche Diagnostics Limited, United Kingdom, due 29 August 2023, outstanding principal 71 million GBP (2011: 35 million GBP; 2010: 35 million GBP), interest rate 5.67%	87	42	41
Total loans receivable – related parties	240	233	285

EUR denominated loans

Loans receivable – related parties *in millions of EUR*

	2012	2011	2010
Roche Deutschland Holding GmbH, Germany, due 25 June 2018, outstanding principal 275 million EUR, interest rate 3.50%	275	-	-
Roche Diagnostics S.p.A., Italy, due 25 June 2018, outstanding principal 175 million EUR, interest rate 3.50%	175	-	-
Roche S.p.A., Italy, due 25 June 2018, outstanding principal 250 million EUR, interest rate 3.50%	250	-	-
Roche Diagnostics S.L., Spain, due 25 June 2018, outstanding principal 150 million EUR, interest rate 3.50%	150	-	-
Roche Farma S.A., Spain, due 25 June 2018, outstanding principal 100 million EUR, interest rate 3.50%	100	-	-
Roche Farmaceutica Quimica, Lda., Portugal, due 25 June 2018, outstanding principal 50 million EUR, interest rate 3.50%	50	-	-
Total loans receivable – related parties	1,000	-	-
Reported as			
- Long-term loans receivable – related parties	1,240	233	285
- Short-term loans receivable – related parties	-	-	-
Total loans receivable – related parties	1,240	233	285

7. Accounts receivable – related parties

The Company deposits surplus funds with Roche Pharmholding B.V. in its function as corporate cash pool leader for numerous Roche affiliates. Amounts deposited are immediately available and bear variable interest referenced to one month LIBOR. As at 31 December 2012 the Company also had interest receivables from Roche affiliates in respect of the loans given (see Note 6).

Accounts receivable – related parties *in millions of EUR*

	2012	2011	2010
Accounts receivable with Roche Pharmholding B.V.	3	13	13
Interest receivables – related parties	22	4	5
Total accounts receivable – related parties	25	17	18

8. Cash and cash equivalents

As at 31 December 2012 the Company had no cash in its bank account (2011: zero EUR).

9. Accrued interest

Accrued interest in millions of EUR

	2012	2011	2010
Interest payable	16	4	5
Total accrued interest	16	4	5

10. Debt

Debt: movements in carrying value of recognised liabilities in millions of EUR

	2012	2011
At 1 January	235	287
Proceeds from issue of notes	996	-
Repayment and redemption of notes	-	(71)
(Gains) losses on redemption and repurchases of notes ²	-	13
Amortisation of debt discount ²	-	1
Currency translation effects	7	5
At 31 December	1,238	235
Consisting of		
- Notes	1,238	235
Total debt	1,238	235
Reported as		
- Long-term debt	1,238	235
- Short-term debt	-	-
Total debt	1,238	235

Issuance of bonds and notes

On 23 March 2012 the Company issued EUR denominated fixed rate 2.0% notes due 25 June 2018 with a principal amount of 1,000 million EUR (ISIN: XS0760139773). The net proceeds were 996 million EUR and the effective interest rate is 2.07%. These notes are guaranteed by Roche Holding Ltd, the parent company of the Roche Group.

In 2011 the Company did not issue any bonds or notes.

Redemption and repurchase of bonds and notes

Partial repurchase of pound sterling-denominated notes: On 5 December 2011 the Company completed a tender offer for a nominal amount of 50 million GBP of the notes due 29 August 2023 with a total principal amount of 250 million GBP. The cash outflow was 71 million EUR, plus accrued interest. The loss on partial repurchase was 13 million EUR. The effective interest rate of the notes repurchased was 5.46%.

Outstanding bonds and notes

Recognised liabilities and effective interest rates of bonds and notes *in millions of EUR*

	Effective interest rate	2012	2011	2010
5.375% notes due 29 August 2023, principal 250 million pounds sterling, outstanding 200 million pounds sterling (ISIN: XS0175478873)	5.46%	242	235	287
2.0% notes due 25 June 2018, principal 1.0 billion euros (ISIN: XS0760139773)	2.07%	996	-	-
Total		1,238	235	287

The fair value of the notes is 1,360 million EUR (2011: 292 million EUR). This is calculated based on the observable market prices of the debt instruments.

There are no pledges on the Company's assets in connection with the debt.

11. Equity

Share Capital

The authorised share capital of the Company consists of 100,000 shares with a nominal value of 100 EUR each of which 20,000 shares have been issued and fully paid in. Roche Pharmholding B.V., a company registered in the Netherlands is the sole shareholder.

Dividends

There were no dividend payments in 2012 (2011: none).

Own equity instruments

The Company holds none of its own shares (2011: none).

12. Contingent liabilities

The operations and earnings of the Company may, from time to time and in varying degrees, be affected by political, legislative, fiscal or regulatory developments, in the countries in which it operates. The nature and frequency of these developments and events, not all of which are covered by insurance, as well as their effect on future operations and earnings, are not predictable. As of 31 December 2012, the Company does not have any material contingent liabilities (2011: none).

13. Related parties

Controlling shareholders

As a member of the Roche Group, all of the Company's related party transactions are with Roche Group affiliates. The transactions include interest on and disbursements/repayments of loans given by the Company. In addition the Company has a current account with Roche Pharmholding B.V., the corporate cash pool leader, as described in Note 7.

Related party transactions *in millions of EUR*

	Year ended 31 December	
	2012	2011
Interest income – related parties ²	41	15
Guarantee fees – related parties ²	(11)	-
Repayment of loans receivable – related parties	-	71
Income from early repayment of loans – related parties ²	-	14
(Increase) decrease of cash pool balance with related parties ⁷	10	-
Issue of long-term loans receivable – related parties ⁶	(1,000)	-

Related party balances *in millions of EUR*

	2012	2011	2010
Long-term loans receivable – related parties ⁶	1,240	233	285
Short-term loans receivable – related parties ⁶	-	-	-
Accounts receivable – related parties ⁷	25	17	18
Accounts payable – related parties	-	-	-

Subsidiaries and associates

The Company has no subsidiaries or associates.

Key management personnel

The purpose of the Company is to act as a financing company for the operations of the Roche Group. The members of the Company's Board of Directors act as the chief operating decision-maker.

Board of Directors of Roche Finance Europe

Bart L.A. Vanhauwere	Chairman	Appointed 1 December 2010
Peter Eisenring	Member of the Board	Appointed 31 January 2003
Johannes W. van den Broek	Member of the Board	Appointed 31 January 2003
Dieter F. Heinis	Member of the Board	Appointed 1 November 2009

The directors did not receive remuneration or payment from the Company for their time and expenses related to their services during 2012 and 2011.

14. Risk management

Roche Group risk management

Risk management is a fundamental element of the Roche Group's business practice on all levels and encompasses different types of risks. At a group level risk management is an integral part of the business planning and controlling processes. Material risks are monitored and regularly discussed with the Corporate Executive Committee and the Audit Committee of the Board of Directors.

Financial risk management

The Company is exposed to financial risks arising from its corporate finance activities of providing financing to other affiliates of the Roche Group and obtaining refinancing on the bond markets. The Company's financial risk exposures are related to changes in interest rates and the creditworthiness and solvency of the Company's counterparties.

Financial risk management within the Roche Group is governed by policies reviewed by the Board of Directors. These policies cover credit risk, liquidity risk and market risk and are also applicable to the Company. These policies provide guidance on risk limits, type of authorised financial instruments and monitoring procedures. As a general principle, the policies prohibit the use of derivative financial instruments for speculative trading purposes. Policy implementation and day-to-day risk management are carried out by the relevant treasury functions and regular reporting on these risks is performed by the relevant accounting and controlling functions within Roche.

Credit risk

Credit risk arises from the possibility that counterparties to transactions may default on their obligations, causing financial losses for the Company. The objective of managing counterparty credit risk is to prevent losses of liquid funds deposited with or invested in such counterparties. The maximum exposure to credit risk resulting from financial activities, without considering netting agreements and without taking account of any collateral held or other credit enhancements, is equal to the carrying value of the Company's financial assets.

Carrying value and fair value of financial assets *in millions of EUR*

By line items in notes	Asset class	2012		2011	
		Carrying value	Fair value	Carrying value	Fair value
Long-term loan receivable – related parties ⁶	Loans and receivables	1,240	1,355	233	290
Accounts receivable – related parties ⁷	Loans and receivables	25	25	17	17
Total		1,265	1,380	250	307

The counterparties to the Company's financial assets are members of the Roche Group and therefore the credit risk ultimately depends on the financial position of the Roche Group.

As at 31 December 2012 the Company has no financial assets which are past due but not impaired (2011: none) and no financial assets whose terms have been renegotiated (2011: none).

Liquidity risk

Liquidity risk arises through a surplus of financial obligations over available financial assets due at any point in time. The Company's obligations to third parties on the bond markets are guaranteed by Roche Holding Ltd, the parent company of the Roche Group and covered by loan receivables from other members of the Roche Group that have the same maturity. In addition, the Company has access (jointly with other borrowers of the Group) to a currently unused committed credit line with various financial institutions of 3.9 billion EUR.

As described in Note 10, at 31 December 2012 the Company had financial liabilities with a principal amount of 200 million GBP due 29 August 2023 (2011: 200 million GBP) and with a principal amount of 1,000 million EUR due 25

June 2018. Interest coupons of 10.7 million GBP are payable annually on 29 August for the GBP denominated notes and 20.0 million EUR are payable annually on 25 June for the EUR denominated notes. There are no other contractual cash flows from financial liabilities.

Market risk

Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices will affect the Company's income or the value of its holdings of financial instrument. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimising the return on risk.

As at 31 December 2012 the Company's exposure to interest rate risk was insignificant, as the outstanding principal amount on the Company's debt (see Note 10) and the loans receivable from related parties (see Note 6) are both at fixed interest rates. The Company's only variable interest-bearing financial asset/liability referenced to one month LIBOR was the receivable balance of 3 million EUR (2011: 13 million EUR) with the corporate cash pool leader (see Note 7).

The foreign exchange risk was also insignificant as the terms of financial assets and liabilities as well as the currency are matching.

Capital

The capital management of the Company is managed within the Roche Group. The Company's objectives when managing capital are:

- To safeguard the Company's ability to continue as a going concern, so that it can continue to provide financing activities on behalf of the Roche Group.
- To maintain sufficient financial resources to mitigate against risks and unforeseen events.

Capital is monitored on the basis of the capitalisation, which is calculated as being debt plus equity. Information on the Company's debt and equity is reported to senior management as part of the Roche Group's regular internal management reporting. The Company's capitalisation is shown in the table below.

Capital in millions of EUR

	2012	2011	2010
Debt ¹⁰	1,238	235	287
Equity	11	11	11
Capitalisation	1,249	246	298

The Company is not subject to regulatory capital adequacy requirements as known in the financial services industry.

Woerden, 28 January, 2013

The Board of Directors

B.L.A. Vanhauwere

J.W. van den Broek

P. Eisenring

D.F. Heinis

Other information



Independent auditor's report

To: the Board of Directors of Roche Finance Europe B.V. Roche Finance Europe B.V.

Report on the financial statements

We have audited the accompanying financial statements for the year then ended of Roche Finance Europe B.V., Woerden, which comprise the statement of financial position as at 31 December 2012, the statements of comprehensive income, changes in equity and cash flows for the year then ended and notes, comprising a summary of the significant accounting policies and other explanatory information.

Management's responsibility

Management is responsible for the preparation and fair presentation of these financial statements in accordance with International Financial Reporting Standards as adopted by the European Union and with Part 9 of Book 2 of the Netherlands Civil Code, and for the preparation of the management report in accordance with Part 9 of Book 2 of the Netherlands Civil Code. Furthermore, management is responsible for such internal control as it determines is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Dutch law, including the Dutch Standards on Auditing. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

ROCHF 13W00101304RTM

KPMG Accountants N.V., registered with the trade register in the Netherlands under number 33263683, is a subsidiary of KPMG Europe LLP and a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative ('KPMG International'), a Swiss entity.



Opinion

In our opinion, the financial statements give a true and fair view of the financial position of Roche Finance Europe B.V. as at 31 December 2012 and of its result and its cash flows for the year then ended in accordance with International Financial Reporting Standards as adopted by the European Union and with Part 9 of Book 2 of the Netherlands Civil Code.

Report on other legal and regulatory requirements

Pursuant to the legal requirements under Section 2:393 sub 5 at e and f of the Netherlands Civil Code, we have no deficiencies to report as a result of our examination whether the management report, to the extent we can assess, has been prepared in accordance with Part 9 of Book 2 of this Code, and whether the information as required under Section 2:392 sub 1 at b - h has been annexed. Further, we report that the management report, to the extent we can assess, is consistent with the financial statements as required by Section 2:391 sub 4 of the Netherlands Civil Code.

Rotterdam, 28 January 2013
KPMG Accountants N.V.

A.A. Kuijpers RA

Appropriation of results for the year 2012

In accordance with Article 21 of the Articles of Association the result for the year is at the disposal of the shareholder.

Proposed profit appropriation

The directors recommend that the entire profit for the financial year of 265,561 EUR is to be taken to reserves. The proposal has been included in the Company's 2012 financial statements.